Earlier today I asked an ASCO official, “What do you think is the biggest, most important news here this weekend.” Off the record, she replied: The antibody drug Ipilimumab.”

I wrote a short blurb about this drug Saturday. Ipilimumab is being developed to help patients with relapsed melanoma. Melanoma is the deadliest form of skin cancer. In a Phase III Trial, patients with advanced, formerly treated melanoma who received the monoclonal antibody ipilimumab lived 34 percent longer than those who receive the current standard of care.

Potentially good news for advanced skin cancer patients who had begun to give up hope.

Feel good and keep smiling! Pat

One thought on “Experimental Monoclonal Antibody Ipilimumab May Help Extend Skin Cancer Patients Lives

  1. Hi friends,

    You have provided a very good site to knowing about Monoclonal Antibody. These are made by identical immune cells that are all clones of a unique parent cell, they can then serve to detect or purify that substance…

Leave a Reply